KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortizatization of Intangibles: 2009-2024

Historic Amortizatization of Intangibles for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $8.3 million.

  • Biomarin Pharmaceutical's Amortizatization of Intangibles fell 49.61% to $978,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 40.21%. This contributed to the annual value of $8.3 million for FY2024, which is 9.57% down from last year.
  • As of FY2024, Biomarin Pharmaceutical's Amortizatization of Intangibles stood at $8.3 million, which was down 9.57% from $9.2 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Amortizatization of Intangibles ranged from a high of $9.2 million in FY2023 and a low of -$5.2 million during FY2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Amortizatization of Intangibles value was $8.3 million (recorded in 2024), while the average stood at $4.8 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Amortizatization of Intangibles tumbled by 809.17% in 2021, and later spiked by 403.25% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Amortizatization of Intangibles stood at -$567,000 in 2020, then slumped by 809.17% to -$5.2 million in 2021, then soared by 40.97% to -$3.0 million in 2022, then spiked by 403.25% to $9.2 million in 2023, then decreased by 9.57% to $8.3 million in 2024.